GPCR Overview
Upcoming Projects (GPCR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GPCR)
-
Looking at the Future of Oral Weight Loss Medications, Including Structure Therapeutics recent Phase 2 data on Aleniglipron and the Uptake of Novo Nordisks Wegovy
Tickers: GPCR, NVO, LLY
Executed On: Apr 09, 2026 at 09:30 AM EDT -
Discussing Structure Therapeutics Report of Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Ticker: GPCR
Executed On: Dec 12, 2025 at 10:00 AM EST -
A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 14, 2024 at 11:00 AM EDT -
Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 13, 2024 at 02:40 PM EDT -
Discussing the Phase 2a clinical trial data on Structure Therapeutics's GSBR-1290 in patients with obesity and type 2 diabetes
Ticker: GPCR
Executed On: Jan 18, 2024 at 11:00 AM EST
Upcoming & Overdue Catalysts (GPCR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (GPCR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
